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Background: EPCs were isolated primarily in 1997 by Asahara et al. and recent studies indicated that bone-marrow-
derived EPCs contributed little to the endothelium of tumor vessels. Tumors of the CNS system demonstrate
various features of angiogenesis.
Methods: EPCs derived from rat bone marrow were isolated and cultured in M199 medium without any induced
factors. EPCs were studied using immunohistochemical staining, Flow cytometry and culture under three-
dimensional condition to determine EPCs’ characteristics in vitro. We also established an animal model by injecting
EPCs marked with Hoechst 33342 into the back of BALB/c nude mice and performed hematoxylin-eosin (HE) and
immunofluorescent staining to study EPCs’ features in vivo. To research effect of EPCs on glioma, animals bearing
tumors model with C6 glioma were established. About 27 day after injection, we performed immunohistochemical
staining and Immunofluorescence staining.
Results: Our results showed that EPCs derived from rat bone marrow appeared typical morphological
characteristics and were positive of CD34, CD133, KDR and CD31 antigens at different time in vitro under the
special M199 medium without any induced factors. The percentage of cells that expressed CD133 decreased
gradually. In brief, the present study showed that EPCs derived from rat bone marrow differentiated into ECs in
medium the without any induced factors and formed tubular structures in three-dimensional circumstances. Animal
experiments suggested that EPCs differentiated into ECs and other else non-endothelial cells, and that EPCs
contributed M199 of glioma.
Discussion: These findings provides some novel results about biological characteristics of EPCs in vivo and ex vivo,
and an update on the effect of EPCs on glioma and which would be helpful for the overall understanding of EPCs
and make EPCs to be implied on the clinical therapy.Background
Since endothelial progenitor cells (EPCs) from peripheral
blood (PB) were initially discovered and identified using
the magnetic cells sorting method in 1997 by Asahara
and his group [1], several researchers have found that
EPCs existed in bone marrow, cord blood, and embryo-
tissues, and that minimal number of EPCs also existed
in heart, big blood vessel, skeletal muscle and fat tissue.
So far, phenotypes of EPCs have remained to be deter-
mined, and exact differentiation has been still an* Correspondence: xiangping64@yahoo.com.cn
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reproduction in any medium, provided the orongoing debate topic. But it is widely accepted that early
EPCs can be defined as CD133+/CD34+/KDR+ cells,
whereas late EPCs are positive for CD34 and VEGFR2,
lose CD133 and begin to express CD31, membrane
molecules typical to mature ECs [1-3].
It was recently reported that EPCs derived from Em-
bryonic Stem cells (ESCs) may be developed to use as a
rapidly-expandable alternative for angiogenic transplant-
ation therapy [4]. But EPCs derived from ESCs have not
been studied extensively. We infer that the obstacle may
be ethic problem. So we would rather select EPCs
derived from rat marrow as our subject in the following
study. Bone marrow-derived EPC played critical role in
postnatal vasculogenesis through pivotal bioactivities,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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proliferation in angiovasculogenic tissues [5].
Researchers generally accept that tumors are endowed
with angiogenic-inducing capability, and critically
dependent on blood vessels for their nutrient and oxy-
gen delivery [6], allowing these cells to grow, invade
tissue nearby, spread to the other parts of the body,
and form new colonies of cancer cells [7, 8], which idea
came to light about fifty years ago when Judah Folkman
and his group demonstrated that neovascularization is
a necessary condition for malignant growth of solid
tumors [9]. However, recent studies indicated that
bone-marrow-derived cells contributed little to the
endothelium of tumor vessels [10].
From the above review, the information about EPCs
and tumors still remains a lot of arguments. We also
observed that almost all of the previous studies were
performed under the special induced circumstances. In-
stead, we have not seen any study of the characteristics
of EPCs under the native condition. In the present study,
we established a EPCs transplantation mice model and a
mice model bearing glioma to further investigate BM-
derived EPCs bioactivity and their effect on the growth
of glioma in native circumstance without any induced
factors.
Materials and methods
All procedures were conducted in accordance with
Chinese laws governing animal care, and were approved
by the Institutional Animal Use and Care Committee of
China.
Isolation and culture of EPCs
The Ficoll density gradient centrifugation, a previously
published method [11, 12], was used to isolate mono-
nuclear cells(MNCs) from rat bone marrow. Isolated
mononuclear cells were cultured in complete medium
199 without any growth factors (M199, Gibco. Ameri-
can) special for EPCs in an atmosphere of humidified
5% CO2 at 37°C. Four-eight hours later, non-attached
cells were reseeded and cultured. To observe EPCs’
morphology, we took photos for the cells during the
period of culture.
Cell proliferation assay
Cell proliferation was analyzed by 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Gibco.,
American) assay as previously described [2]. In brief,
200ul medium per well containing 2 × 103 cells were
seeded in 96-well microtiter plates. Twenty-four hours
later, cells were subjected to MTT assay, EPCs were sup-
plemented with 20 ul MTT (5 mg/ml) and incubated for
another 4 h. The supernatant was discarded and the
EPCs preparations were shacked in 200ul dimethylsulfoxide (DMSO, Gibco., American) for 10 min, fol-
lowed by measurement of optical density value at
570 nm. Results from three independent experiments in
triplicates were presented. The OD values were normal-
ized to the blank control cells. We performed the above
assay every other day until cells were grown to more
than 95% confluency in the plates.
Immunofluorescence
To determine the expression of CD34, CD133, KDR and
CD31, the primary and 2nd passage EPCs were reseeded
on glass coverslips in 6-well plate and were harvested
several days later and fixed in 4% paraformaldehyde for
30 min. After washing three times with 1x PBS contain-
ing 1% Triton X-100 for 5 min, slides were then blocked
with normal goat serum for 1 h at 4°C and then incu-
bated with primary antibodies(rabbit anti-rat CD34,
CD31, KDR and CD133 antibodies, Santa Cruz Co.,
American) (1:200) in a dark and moist chamber over-
night at 4°C. After washing with 1x PBS for 3× 5 min,
slides were incubated with relevant secondary antibodies
(PE and FITC-conjugated goat anti-rabbit IgG, Santa
Cruz Co., American) (1:500) for 1 h at room
temperature. Slides were then washed three times with
1x PBS for 5 min and air dried, and covered onto glass
slides with the mounting medium. The stained cells were
observed under laser confocal scanning microscopy
(Nikon Co., Japan) at once.
Flow cytometry
To assess the dynamic change of surface antigen CD133
of cells, we performed fluorescence-activated cell sorter
(FACS) analysis. Freshly-isolated MNCs were cultured
for 10 days, 15 days, 20 days, 21 days and then har-
vested. The collected cells were blocked with normal
goat serum for 1 h at 4°C and then incubated with goat
anti-rat CD133 antibody (1:200) 4 h at 4°C. After wash-
ing with 1000rmp for 5 min, cells were incubated with
FITC-conjugated goat anti-rabbit IgG (1:500) for 2 h at
4°C. After washing with 1000rmp for 5 min, cells were
resuspended with 300ul PBS each tube and were exam-
ined quantitatively using Flow cytometry and CellQuest
software (Becton DickinAson, Heidelberg, Germany) at
once. The CD133-positive cells at different time were
calculated as percentage of all MNCs. Each analysis
included 100,000 events.
Three-dimensional cell culture in vitro
A specific culture medium containing rat tail collagen
for EPCs was used to make three-dimensional medium.
2 × 105 EPCs were seeded in a 24-well plate in the mid-
dle of the two layers three-dimensional medium and cul-
tured in an atmosphere of humidified 5% CO2 at 37°C.
After 3 days of incubation, image of tubular structures
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power lens and the total number of tube formation at
400x visual fields for each well were calculated. Three
separate experiments were performed.
EPCs transplantation animal model
To study the characteristics of EPCs in vivo, the collected
EPCs marked with Hoechst 33342 were utilized to estab-
lish a EPCs transplantation animal model. Briefly, 1 × 107
EPCs were injected subcutaneously into both sides of the
spine of 6-week-old SCID mice (n = 6). At the same time,
PBS solution was also subcutaneously injected into both
sides of the spine of 6-week-old SCID mice as a negative
control (n = 6). We daily measured the volume of the
subcutaneous tumor-like outgrowth formed by EPCs by
a vernier caliper and calculated by the formula: Volume=
L(Length) ×w2(Width) × 0.52, which was previously pub-
lished [13]. According to the above data, we drew a
growth curve of the subcutaneous bulge.
After transplantation fifty days, the animals were
euthanized and tumor-like outgrowth were removed and
frozen in liquid nitrogen. Cryosections and paraffin sec-
tion were prepared respectively for immunofluorescence
staining with CD34, CD31, KDR antibodies and HE
(hematoxylin-eosin) staining.
Effect of EPCs on glioma
We utilized a rat C6 glioma transplantation model to
study the effect of EPCs on glioma in vivo. In brief,
Mixed cells suspensions containing 2 × 106 rat C6 cells
and 2 × 106 EPCs/100 ul were injected subcutaneously
into one flank of 6-week-old SCID mice (n = 10),called A
group. At the same time, 2 × 106 rat C6 cells were also
subcutaneously injected into another flank of 6-week-old
SCID mice as a negative control, called B group. Method
of measuring the size of tumors was the same as
described above.
After transplantation 27 days, the animals were eutha-
nized and tumors were removed and frozen in liquidFigure 1 (10×) A. the appearance of adherented EPCs within 24 h; B.
were connected with each other at the 7th days; D. EPCs grew quickl
appearance at the 11th days.nitrogen and fixed in 10% formalin respectively. Cryo-
sections and paraffin sections of 10 um were prepared
respectively for immunofluorescence (ICH) staining with
CD34, CD31, KDR antibodies and Immunohistochemis-
try staining.
Immunohistochemistry staining was used to detect if
CD31 antigen expressed and how much expressed in the
tumors exnografts. Immunohistochemistry processes
was accorded to the instruction of the reagent kit. The
goat-anti-rat CD31 antibody (1:200) was applied as pri-
mary antibody. Peroxidase -conjugated goat-anti-rabbit
IgG (1:500) as secondary antibody.
Stained tumor sections were scanned at low power,
and the areas of greatest CD31-positive density were
chosen for quantification of vessel density. In addition,
to evaluate the quantitative change in tumor vasculature,
micro-vascular density (MVD) was estimated on CD31
immunostained sections. The number of micro-vessels
was counted under microscope in eight fields and the
mean MVD was calculated to the average number of
micro-vessels.
Results
Morphological features of EPCs
After culture for 24 h, a few of cells attached to the cul-
ture flask, cells were characterized by conglobate cell
body and clear cytoplasm (Figure 1A). During 2–6 days
of culture, cells became spindle-shape. Some of cells
began to connect with each other and exhibited linear
cord-like structures (Figure 1B). After 6 days of culture,
the adjacent cells continued to connect and formed col-
onies (Figure 1C). Approximately 11 days after MNCs
were cultivated, cells colonies gradually reached 100%
confluence and appeared typical cobblestone-like mono-
layer (Figure 1D).
Proliferation of EPCs
The primary EPCs showed the following growth feature:
during 1 to 3 days of culture, cells grew slowly. From 4CFUs and Linear structure formed by EPCs at the 4th day; C. CFUs
y and covered the bottom of the flask with cobblestone-like
Figure 2 The growth curve of EPCs.
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grew slowly again (Figure 2).
Immunofluorescence staining of EPCs
The primary passage EPCs were collected and reseeded
on the glass coverslips in 6-well plate. After 2 days of cul-
ture, cells were used to identify the surface antigen
(CD34, CD133 and KDR). Data showed that cells were
positive with the above three antigens (Figure 3A-C). The
2nd passage EPCs were collected and reseeded on the
glass coverslips in 6-well plate. After 2 days of culture,
cells were used to identify the surface antigen of cells
(CD34, CD31 and KDR). Data showed that cells were
positive with the above three antigens (Figure 3D-F).
The dynamic change of surface antigen CD133 of cells
At the day 10,15,20,21, CD133-positive rate of MNCs
were 46.8%,18.1%,2.73%,1.58% respectively (Figure 4A-
D). However, the control was only 0.99% (Figure 4E).Figure 3 A–C(10×) At the 2nd day, cells expressed antigen KDR (Red)
day, cells expressed antigen KDR (Red), CD31(Green),CD34(Green) resWith the time flied away, CD133-positive rate became
gradually lower till lost. After culture for 20 days, the
percentage of cells that expressed CD133 decreased dra-
matically compared with that of the 15 days (P<0.05).
Tubular structures formed by EPCs in vitro
On day 5 of Three-dimensional cell culture, tube-like
structures were observed by invert light microscope with
high power lens (Figure 5). There were 3 tube-like struc-
tures on each visual field (40×).
Subcutaneous formation of EPCs in vivo
After 20 days transplantation, subcutaneous outgrowth
with the volume of 0.13 cm3 formed by EPCs was
observed, and then grew bigger and bigger until the ani-
mals were euthanized and tumor-like formations were
removed at 50 day. According to the volume of the sub-
cutaneous outgrowth from EPCs, we drew a growth
curve of it (Figure 6), data showed that EPCs xenografts
seemed to be aging.
Differentiation of EPCs in vivo
Paraffin sections were performed HE (hematoxylin-
eosin) staining, data showed that there were three kinds
of structures of samples, they were vessel-like endothe-
lial network formation, muscle-like tissue and fat-like
cells respectively (Figure 7A). Meanwhile, we observed
cells marked with Hoechst 33324 (Figure 7B).
Immunofluorescence staining of exnograft derived from
donors EPCs
The immunofluorescence assay revealed, firstly, both CD
34 and Hoechst 33342 positive cells appeared in the same
visual (Figure 8A-B). Secondly, EPCs, which expressed, CD133(Green),CD34(Green) respectively; D–F(40×) At the 21st
pectively.
Figure 4 A–D Marrow-derived EPCs were detected by Flow cytometry and expressed antigen CD133 at the 10th, 15th, 20th, 21st day.
4E. It was the negative control.
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the tumor (Figure 8C-D). Finally, both Flk1 and Hoechst
33342 positive cells were observed in the same visual too
(Figure 8E-F). It also proved that EPCs expressed blue
fluorescence were donor-derived endothelial progenitor
cells.
The data showed that EPCs derived from donors could
differentiate into endothelial cells, which expressed
CD34, KDR and CD31 antigens, in the SCID-mice. But
we also observed that cells marked with Hoechst 33342
did not express the above three antigens, which sug-
gested that some of EPCs derived from donors must
have been able to differentiate into other else non- endo-
thelial cells.
Growth of the transplantation tumor
About 9 days after C6 glioma cells with or without EPCs
were injected into animals, subcutaneous tumors were
observed. The mean volume of the experimental group
tumor was (0.21±0.005)cm3, the control group was (0.18
±0.003)cm3. After that, the volume of the tumors were
measured every 3 days. After transplantation 27 days,
the animals bearing tumor were euthanized and tumorsFigure 5 (40×) Three-dimensional cells culture, tube-like
structures were observed.were removed. As summarized in Figure 9A, the size of
tumors of A group were significant bigger compared to
the control, B group(P<0.05), and at the same time, the
quality of A group was (1.75±0.13)g, while the quality of
B group was (1.12±0.11)g (Figure 9B)(P<0.05).
Immunohistochemistry staining of glioma exnografts
About 27 days after cells were injected subcutaneously
into mice, huge tumors were harvested from two groups
mice. To evaluate the mean microvascular density
(MVD) of the tumors, we performed immunohistochem-
istry staining with CD31 antibody and quantified the
rate of CD31 positivity. Data revealed that tumors exhib-
ited brown cytoplasmic staining in both controls and ex-
perimental groups, which suggested that tissues of the
tumors expressed positively CD 31 antigen. We selected
five different microscopic fields at random and counted
the number of CD31-positive cells per field. (30 ± 1.2)
cells were CD31-positive in A group, whereas (18 ± 1.0)
cells were positive for CD31 in B group. According to
the brown staining expression, we evaluated the mean
microvascular density (MVD), the above results indi-
cated that EPCs significantly increased the extent of
MVD in the tumors (p<0.05) (Figure 10). In addition,Figure 6 The growth of subcutaneous vegetation from EPCs.
Figure 7 A–B HE staining of subcutaneous vegetation from
EPCs, at the same field cells marked with Hoechst 33324 were
observed. (10×) A. HE staining of the subcutaneous processes;
B. EPCs marked with Hoechst 33342.
Figure 9 A the volume of tumors of A group and B group at
the 27th day(P<0.05). B the weight of tumors of A group and B
group at the 27th day(P<0.05).
Zhang et al. Cancer Cell International 2012, 12:32 Page 6 of 9
http://www.cancerci.com/content/12/1/32immunohistochemical data from the xenograft studies
were presented (Figure 11A-B).
Immunofluorescence assay of glioma exnografts
Immunofluorescence staining showed that cells, expressed
simultaneously CD34,CD133,KDR and Hoechst 33342,
appeared in the tumors (Figure 12A-F), which proved
that EPCs derived from donors incorporated into the
tumors and contributed to the growth of glioma.
Discussion
The present study demonstrated that MNCs could be
separated by a method of Ficoll density gradient centri-
fugation from rat bone marrow, consistent with previous
reports [10, 11]. EPCs were isolated primarily in 1997 by
Asahara et al. [1], and since then has been extensively
studied not only in biologic characteristics but functional
implication. EPCs have been shown to express the endo-
thelial cell surface antigens CD34, KDR and stem cell
surface antigens CD133, and uptake AcLDL, so we canFigure 8 A/B(20×) A. cells expressed antigen CD34(green); B. cells lab
D. cells labled with Hoechst 33342(blue). E. cells expressed antigen CD31(gisolate or identify by these markers [11-15]. EPCs could
be counted as CD34+ CD45low CD133+ VEGFR2+ cells
by flow cytometry [16]. The recent study reported that
besides of the above markers, EPCs expressed also VDR,
and cells co-expressed CD34(+)/CD133(+/−)/KDR(+)
and VDR seem to be influenced by uremia-relatedled with Hoechst 33342(blue). C. cells expressed antigen Flk1(green);
reen); F. cells labled with Hoechst 33342(blue).
Figure 10 The microvascular density of tumor of the test group
and the control group at the 27th day(P<0.05).
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(OH)D serum levels and calcitriol therapy [17]. In the
current study, EPCs derived from rat bone marrow
expressed CD34, CD133 and Flk1/KDR/VEGFR2, which
were proved by Immunohistochemical staining.
Flow cytometry analysis also revealed that during the
procedure of culture, another stem cell marker, CD133,
was in the dynamic changing state, which was only
expressed at the early period of MNCs culture but was
gradually reduced thereafter, indicating that CD133
seems to be a marker of early EPCs in bone marrow. In
contrast, several recent studies suggested that CD31 was
little expressed initially (i.e., in freshly isolated circulat-
ing MNCs) but gradually appeared after cultured for
several passages. These results suggested that CD133Figure 11 A–B (20×) HE staining of A and B group tumors.
C–D (10×) antigen CD31 immunohistochemistry staining in the A
and B group.seems to be a marker of early EPCs, whereas CD31 will
be used as a marker for differentiated EPCs.
The typical morphology features of EPCs, adherent
colonies with a cobblestone profile, also appeared in our
study, which is consistent with that described previously
[1, 18]. Furthermore, another independent experiment,
three dimensional cultured in a rat tail collagen stereo
model in vitro, proved that functional EPCs could be
expanded from the primary culture of MNCs obtained
from rat bone marrow under M199 medium without
any induced factors, and that culture-expanded EPCs
could developed into tube-like network formation
in vitro, which is an interesting finding and not reported
up to now.
Another interesting finding of the present study is as
follows. We employed an immunodeficient nude mouse
as a transplanted subject and EPCs-derived from bone
marrow were injected subcutaneously into both sides of
spinal column of an immunocompromised mouse. After
fifty days, tumor-like outgrowth from transplanted EPCs
are harvested and then investigated. The results indi-
cated that EPCs-derived from bone marrow could differ-
entiate into endothelial cells and non- endothelial cells,
such as muscle-like cells and fatty-like cells without any
induced factors. However, we cannot answer what is
their precise identification, which is one of the major
limitations of the current study.
Previous studies indicated that endothelial progenitor
cells (EPCs) in bone marrow and peripheral blood con-
tributed to tissue repair in various pathological condi-
tions via the formation of new blood vessels [19].
Nevertheless, it has been documented that EPCs could
specially home and incorporate into sites of physio-
logical vessel formation in vivo and incorporate into the
vasculature of tumors, ischemic skeletal and cardiac
muscle, and ulcers [20-22]. It is well known that the piv-
otal process of tumor growth and metastasis is angio-
genesis. In clinical, more and more anti-angiogenesis
drugs have been developed to control this process [23,
24]. Angiogenesis is a complex process and its mechan-
isms still remain unclear. Malignant glioma tends to be
highly vascularized, particularly glioblastoma, which are
associated with florid microvascular proliferation [25].
We also demonstrated that transplantation of both
culture-expanded EPCs from MNCs and C6 glioma aug-
mented neovascularization in experimental animals-
bearing tumor, which was similar with other reports [26,
27], though the culture condition of EPCs is different
between our study and other’. We also found that previ-
ous studies all employed rat tail collagen fibronectin
matrix as solid braces injected subcutaneously into the
subject animals, but it was reported that Matrigel could
induce cord formation from several non-endothelial cells
including fibroblasts [28], baby murine kidney cells [29],
Figure 12 A/B(20×) cells of the test group tumor tissue expressed antigen CD31(red)and Hoechst 33342(blue). C/D(20×) cells of the test
group tumor tissue expressed antigen Flk1(red) and Hoechst 33342(blue). E/F(20×) cells of the test group tumor tissue expressed antigen CD133
(red) and Hoechst 33342(blue).
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CD14+ monocytes seeded in Matrigel [31].
In summary, the current paper provides some novel
findings about biological characteristics of EPCs in vivo
and ex vivo, and an update on the effect of EPCs on gli-
oma. We believe that these data would be helpful for the
overall understanding of EPCs and make EPCs to be im-
plied on the clinical therapy.
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